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Neuroblastoma, the major cause of infant cancer deaths, results from fast proliferation
of undifferentiated neuroblasts. Treatment of high-risk neuroblastoma includes
differentiation with retinoic acid (RA); however, the resistance of many of these tumors
to RA-induced differentiation poses a considerable challenge. Human achaete-scute
homolog 1 (hASH1) is a proneural basic helix-loop-helix transcription factor essential
for neurogenesis and is often upregulated in neuroblastoma. Here, we identified a novel
function for hASH1 in regulating the differentiation phenotype of neuroblastoma cells.
Global analysis of 986 human neuroblastoma datasets revealed a negative correlation
between hASH1 and neuron differentiation that was independent of the N-myc (MYCN)
oncogene. Using RA to induce neuron differentiation in two neuroblastoma cell lines
displaying high and low levels of hASH1 expression, we confirmed the link between
hASH1 expression and the differentiation defective phenotype, which was reversed by
silencing hASH1 or by hypoxic preconditioning. We further show that hASH1 suppresses
neuronal differentiation by inhibiting transcription at the RA receptor element. Collectively,
our data indicate hASH1 to be key for understanding neuroblastoma resistance to
differentiation therapy and pave the way for hASH1-targeted therapies for augmenting
the response of neuroblastoma to differentiation therapy.
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INTRODUCTION
Neuroblastoma, a malignant tumor derived from the sympathetic nervous system, represents one
of the most common solid childhood tumors. They are classified into different stages based on
genetic profile, age of onset, and tumor stage, with amplification of the N-myc (MYCN) gene seen
in 22% of primary tumors and associated with worse clinical outcome (Cohn et al., 2009; Brodeur
and Bagatell, 2014). Gene expression profiles suggest neuroblastomas to be locked in development
at an early stage, being irresponsive to the normal cues that trigger differentiation. They, however,
have the capacity to differentiate into mature cells in response to a variety of physiological and
pharmacological agents. Thus, retinoic acid (RA), by its ability to induce differentiation, remains
the first line of therapy for high-risk neuroblastoma (Reynolds et al., 2003). The greatest obstacle to
differentiation therapy lies in their refractiveness to RA and it is therefore desirable to understand
the mechanisms of resistance and to identify means by which to improve RA effectiveness.
The transcription factor achaete-scute homolog 1 protein (hASH1 for human and Mash1 for
mammalian), encoded by the achaete-scute complex-like 1 (ASCL1) gene and hereafter referred
to as hASH1, is expressed in neural crest cells and neural crest derived progenitor cells of the
sympathoadrenal system and is required for neurogenesis (Castro et al., 2011; Imayoshi et al., 2013;
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Jacob et al., 2013). The hASH1 transcriptional program and
regulation of its activity have been well documented (Castro et al.,
2011; Imayoshi et al., 2013; Huang et al., 2014; Raposo et al., 2015;
Wylie et al., 2015). Detailed characterization of the transcription
factor activity has previously revealed that it activates target
genes involved in both proliferation and differentiation that are
associated with its oscillatory or sustained mode of expression,
respectively (Castro et al., 2011; Imayoshi et al., 2013). During
development, hASH1 expression is mostly restricted to the
embryonic state, being regulated spatially and temporally
primarily by transcriptional inhibition by the Notch pathway
(Axelson, 2004; Huang et al., 2014). hASH1 is also regulated by
post-transcriptional mechanisms involving both mRNA stability
and translation (Fähling et al., 2009; Benko et al., 2011). One such
important post-transcriptional regulator of hASH1 expression
is the heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP
A2/B1) and its role has been described in neuroblastoma cells
exposed to hypoxia, indicating that low oxygen tension could be
an important determinant of neuroendocrine development and
tumor development (Kasim et al., 2014). Surprisingly, aberrantly
high levels of hASH1 have been detected only in neuroblastoma
cell lines; these being mostly derived from highly malignant
tumors and high hASH1 levels thus associated with poor clinical
outcome (Isogai et al., 2011). Gaining insight into the regulatory
cues leading to hASH1 down-regulation during development
could therefore be important for understanding neuroblastoma.
Consistently, expression of hASH1 is down-regulated during
differentiation, independent of differentiation agent. Whether
the down-regulation of hASH1 is essential for differentiation
or a consequence thereof could not be clearly established as
stable cell clones of the SH-SY5Y cell line expressing high
levels of hASH1 were not tolerated (Söderholm et al., 1999).
Thus, a functional link between hASH1 expression and the
responsiveness of neuroblastoma to differentiation remains
elusive (Söderholm et al., 1999; Grynfeld et al., 2000).
Here, we exploit two neuroblastoma cell lines, Kelly and
SH-SY5Y as paradigms of malignant tumors expressing
endogenously high and low levels of hASH1, respectively,
to investigate the functional importance of hASH1 in
neuroblastoma. By analysis of three publicly available microarray
datasets of human neuroblastoma patients (n = 986) and by
experiments performed in the above mentioned cell lines, we
identify a crucial role for hASH1 in regulating the differentiation
potential of neuronal cells via its ability to repress RA-mediated
transcription. These results not only expand the repertoire
of hASH1 functions but also help to explain and eventually
overcome the refractiveness of many neuroblastomas to
differentiation therapy. Our data further reveal the functionality
of hASH1-targeted therapies for augmenting the response of
neuroblastoma to differentiation therapy.
MATERIALS AND METHODS
Microarray Data Analysis
We used the R2: Genomics Analysis and Visualization web tool
to find genes correlated with hASH1 (ASCL1). We included the
following three public datasets for analysis: the Versteeg dataset
(GSE16476) which included 88 human neuroblastoma samples
(Valentijn et al., 2012), the Asgharzadeh dataset (Therapeutically
Applicable Research to Generate Effective Treatments initiative1)
included 249 human neuroblastoma samples (Russell et al.,
2015) and the Kocak dataset (GSE45547) with 649 human
neuroblastoma samples (Kocak et al., 2013), all with different
clinical characteristics. We applied a p-value cut-off of 0.01 for
the correlation coefficient (R value) to obtain significantly
correlated genes. The p values were corrected for multiple
testing according to the false discovery rate. Only for the
Kocak dataset that yielded >4500 correlated genes, we applied
an additional R-value cutoff of ≤ −0.3 or ≥ +0.3. Gene
ontology (GO) analysis (database release date 2016-04-23), using
the Bonferroni correction for multiple testing and a cutoff
p value < 0.05, was independently performed on the list of
significantly correlated genes obtained from each of the three
datasets.
Cell Culture and Treatments
The human neuroblastoma cell lines, Kelly (ACC 355) and
SH-SY5Y (CRL-2266), were grown at 37◦C, 5% CO2 in RPMI
medium supplemented with 10% Fetal Bovine Serum (FBS).
Cells were differentiated with 1 µM and 10 µM all-trans
RA for the indicated times. For shorter treatment times (up
to 24 h), cells that had outgrowths greater than the length
of the cell body were considered to be expressing neurites.
For longer treatment times (4 days), cells that had one or
more outgrowths that reached at least double the diameter
of the cell body were considered to be differentiated. For
hypoxia, a hypoxic chamber set at 1% O2, 37◦C and 5% CO2
was used.
Antibodies
The following antibodies were used: mouse monoclonal
anti-Mash1 (murine homolog of hASH1; BD Pharmingen),
mouse monoclonal anti-hnRNP-A2/B1 (Acris Antibodies,
Rockville, MD, USA), rabbit polyclonal anti-tubulin
(Proteintech), rabbit polyclonal anti-neurofilament L
(Proteintech). Secondary antibodies used were donkey
anti-rabbit and goat anti-mouse IgG-HRP (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The Cy3-coupled
secondary antibody for immunofluorescence was from Jackson
ImmunoResearch Laboratories.
Protein Isolation and Western Blot
Total cellular extracts were prepared by direct lysis of cells in
50 mM Tris (pH 6.8) buffer containing 4 M Urea and 1% SDS.
Western blotting was performed as previously described (Fähling
et al., 2006).
Real Time PCR Analysis
Total RNA was prepared using RNA-Bee (Biozol Diagnostica
Vertrieb GmbH) and real-time PCR experiments performed
1http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html
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as previously described (Kasim et al., 2014). Each sample was
measured in triplicate. mRNA expression levels were normalized
to 18S rRNA using the∆∆Ct method. Primer sequences used are
listed in Supplementary Table S1.
RNA Interference
Control siRNA and siRNA targeting hASH1 and hnRNP-
A2/B1 was transfected into Kelly cells using SilenceMag (Oz
Biosciences) or DharmaFECT 2 (Thermo Scientific, Waltham,
MA, USA) as specified by the manufacturer. All siRNAs were
purchased as SMARTpool siRNAs from Thermo Scientific
Dharmacon. Cells were analyzed 48 h post-transfection for
knock-down efficiency or used for further experiments at 24 h
or 48 h post-transfection.
Cell Transfection and Luciferase Reporter
Assays
Control and backbone vectors were purchased directly from
Clontech and Promega. For knock-down and overexpression
experiments, cells were grown in 24-well plates. Following 24 h
knockdown in Kelly cells, a control luciferase (CONTROL-
LUC) plasmid or the RA receptor element containing
luciferase plasmid along with the renilla luciferase phRL-TK
vector (Promega) was co-transfected using PolyMag (Oz
Biosciences). For over-expression of hASH1 in SH-SY5Y,
a pCMV-Sport6-hASH1 plasmid or control plasmid was
co-transfected with the reporter constructs. After an
overnight incubation, the medium was changed and RA
was supplemented at a final concentration of 1 µM. Cells
were grown for an additional 18 h. Luciferase activity was
measured using the Dual-GloTM luciferase assay system and
the data collected using a luminometer (Berthold Detection
Systems). Co-transfection of hASH1 with EGFP in SH-SY5Y
was performed in 6-well plates with a final concentration
of 2 µg DNA. The ratio of hASH1 to EGFP plasmid was
maintained at 9:1.
Microscopy
The cell nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). Immunofluorescence was performed as
recommended in the antibody data sheet. An epifluorescence
microscope (Axiovert100, Carl Zeiss, Berlin, Germany)
connected to a digital camera (SPOT RT Slider, Diagnostic
Instruments, Sterling Heights, MI, USA) with SPOT software
(Universal Imaging Corp., Marlow Buckinghamshire, UK) was
used for image acquisition. Where indicated, image analysis
was performed using the ImageJ software with the NeuronJ
plugin.
Statistics
If not indicated otherwise, all values are presented as mean± SD
of at least three independent experiments, each with three
biological replicates. Student’s paired t test was applied to
reveal statistical significances between two samples. To compare
means of three or more groups, a one-way ANOVA was used.
p< 0.05 was considered significant.
TABLE 1 | Number of genes correlated with human achaete-scute
homolog 1 (hASH1) and N-myc (MYCN) in human neuroblastoma.
DATASET Number Number of correlated genes∗
of samples hASH1 MYCN
Negative Positive Negative Positive
Versteeg 88 103 366 1050 1148
Asgharzadeh 249 574 1355 3456 2405
Kocak 649 4528 4655 5896 5732
∗
A cutoff of p < 0.01 was used.
RESULTS
hASH1 Is Negatively Correlated with
Genes Involved in Neuron Differentiation in
Neuroblastoma Patients
We first identified genes correlated with either hASH1 or
MYCN, the latter being a well-known proto-oncogene with
clearly established prognostic value in neuroblastoma patients.
We analyzed three datasets that are deposited in the R2Genomics
Analysis and Visualization platform2: the Versteeg dataset
included 88 patient samples (Valentijn et al., 2012), the
Asgharzadeh dataset contained 249 patient samples (Russell
et al., 2015) and the Kocak dataset contained 649 patient
samples (Kocak et al., 2013) (Table 1). The overall small
number of genes correlated with hASH1 relative to MYCN
highlights the specificity of its putative target group (Table 1).
With focus on hASH1, we further narrowed our list for
the Kocak dataset to the top most correlated genes by
setting a cut off for the correlation coefficient (R value) of
≤ −0.3 or ≥ +0.3, which reduced the number of negatively
and positively correlated genes to 419 and 809, respectively.
The list of identified genes correlated with hASH1 for all
three datasets along with their associated R and p values is
given in Supplementary Tables S2–S4. We next performed
gene ontology analysis3 in order to determine the significantly
enriched biological processes (p ≤ 0.05) in these gene lists.
Notably, the enriched biological processes were consistent
with the known functions of hASH1 in cell proliferation and
differentiation (Castro et al., 2011). This is exemplarily shown in
Figure 1A for the negatively correlated genes identified in the
Kocak dataset, which contained the largest number of patient
samples. We observed a striking association of the negatively
correlated genes predominantly with processes involved in
neuron projection development (e.g., regulation of neuron
differentiation, regulation of neurogenesis, regulation of cell
projection organization) and neuron projection morphogenesis
(e.g., neuron development, neuron differentiation, generation
of neurons). These findings were independently validated in
the Asgharzadeh dataset (Supplementary Table S5). Despite the
smaller number of negatively correlated genes in the Versteeg
dataset, the only significantly enriched biological processes
belonged to the category ‘‘regulation of neuron projection
2http://hgserver1.amc.nl/cgi-bin/r2/main.cgi
3http://geneontology.org/
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FIGURE 1 | Human achaete-scute homolog 1 (hASH1) is negatively correlated with genes associated with neurite outgrowth in neuroblastoma.
(A) Enrichment of Gene ontology (GO) biological processes in the 419 genes negatively correlated with hASH1 (R value < −0.3 and with a p value < 0.01) using the
Kocak dataset (Kocak et al., 2013). This corresponds to the top 10% of the strongest correlated genes. A detailed view of all the categories related to regulation of
neuron projection development and neuron projection morphogenesis is shown on the right. Each biological process is color coded according to its GO analysis p
value as shown and the number of genes identified is also indicated. (B) Genes negatively correlated with hASH1 and N-myc (MYCN) were compared. GO analysis
was performed separately for genes correlated with either MYCN or hASH1 and for the genes associated with both. A detailed list of all the GO processes and
associated p values is provided in Supplementary Table S6. Note that the genes correlated only with hASH1 belong to the GO categories of neuron projection
morphogenesis and development.
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FIGURE 2 | Response of neuroblastoma cell lines to retinoic acid (RA)-induced differentiation is dependent on their hASH1 levels. (A) hASH1 and
heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) mRNA as determined in Kelly and SH-SY5Y cells by real-time PCR. Values were normalized to 18S
ribosomal RNA and significant differences between the cell lines indicated with asterisks (∗∗∗p < 0.001, n = 6). (B) Western blot analysis of hASH1 and hnRNP
A2/B1 protein levels in Kelly and SH-SY5Y cells. Tubulin served as a loading control. ∗∗p < 0.01 and ∗p < 0.05. Error bars indicate standard deviation (n = 6).
(C) Quantitation by Western blot of the time-dependent decrease in hASH1 levels in Kelly and SH-SY5Y cells upon 1 µM RA treatment. (D) Phase contrast images
(Continued)
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FIGURE 2 | Continued
showing the time-dependent phenotypic response to 1 µM RA. Note that RA
treatment causes outgrowth of neurite-like processes in SH-SY5Y cells, but
not in the Kelly cells. (E) Percentage of neurite containing cells were defined as
cells with at least one neurite extension greater than the length of the cell
body. More than 100 cells for each cell type and treatment were counted
using ImageJ software, and the percentage of cells with neurite extensions are
indicated. ∗p < 0.05, nc: not counted as no cells matching the above criteria
were observed, and ns = not significant. Error bars indicate standard deviation
(n = 3).
development’’, thus further supporting a negative influence of
hASH1 on neuron differentiation (Supplementary Table S5).
While a myriad of biological processes were highly represented in
the positively correlated genes in all three datasets, we found that
they were enriched for GO biological processes corresponding to
various aspects of the cell cycle (e.g., G1/S phase transition, G2/M
transition of the mitotic cell cycle, mitotic interphase, spindle
checkpoint), DNA replication (e.g., DNA strand elongation,
DNA metabolic processes), telomere maintenance and DNA
damage response and repair (e.g., double-strand break repair,
cellular response to DNA damage stimulus; Supplementary Table
S5). Compared to the positively correlated genes, the negatively
correlated genes had fewer biological processes associated with
them, and the level of significance was lower (p ≥ 10−16 vs.
p ≥ 10−96 for processes associated with the positively correlated
genes). However, processes involving neurogenesis and neuron
differentiation were the only significant associations among the
negatively correlated genes that were consistently seen across
all three datasets (Supplementary Table S5). We also identified
a significant association of hASH1 with neuroblastoma stage
and MYCN amplification status, pointing to its functional
importance in neuroblastoma (Supplementary Figures S1, S2).
To exclude MYCN from mediating this effect, we compared
the profile of genes correlated with both hASH1 and
MYCN (Figure 1B). Despite the high overlap of genes
(280/419 genes) between the two, the GO processes neuron
projection morphogenesis and regulation of neuron projection
development were significantly over-represented in the 139 genes
not correlated with MYCN, highlighting hASH1 function in
regulating these processes (Figure 1B). Interestingly, GO
analysis of the MYCN correlated genes identified primarily
categories associated with the immune response (e.g., T-helper
1 type immune response, regulation of T cell proliferation, T
cell selection, interferon gamma mediated signaling pathway;
Supplementary Table S6). These findings were corroborated in
both of the other datasets (data not shown). Together, these gene
expression data from three independent experiments containing
a total of 986 human neuroblastoma samples reveal a significant
negative correlation between hASH1 and genes involved in
neuron differentiation in neuroblastoma that is independent of
MYCN function.
Characterization of RA-Induced
Differentiation in Neuroblastoma Cell Lines
To reconcile these findings with the known function of
hASH1 in neurogenesis, we postulated that an increase in
hASH1 expression would have an inhibitory influence on
neuron differentiation. Therefore, to investigate the effect
of hASH1 levels on neuron differentiation, we selected two
neuroblastoma cell lines derived from metastatic bone tumor
biopsies, Kelly and SH-SY5Y, expressing endogenous high
and low levels of hASH1, respectively. As neuroblastomas
are also genetically characterized based on their genomic
MYCN amplification status and given the observed correlation
with hASH1 (Supplementary Figure S2), the Kelly cells with
the MYCN-amplified genome and the MYCN-non-amplified
SH-SY5Y cells also enabled us to dissect the contribution
of hASH1 independent of MYCN amplification. Since we
have previously shown that hASH1 is regulated by hnRNP
A2/B1 (Kasim et al., 2014), we monitored the levels of both
hASH1 and hnRNP A2/B1 in these cells. Real-time PCR
analysis revealed higher levels of both hASH1 and hnRNP
A2/B1 mRNA in Kelly vs. SH-SY5Y cells (Figure 2A). Western
blot analysis confirmed the high levels of hASH1 protein
in Kelly cells and the relatively low levels in SH-SY5Y
cells (Figure 2B), the multiple protein bands likely reflecting
post-translational modifications (Wylie et al., 2015). We detected
overall lower hnRNP A2/B1 protein levels in SH-SY5Y than
in Kelly cells, which was primarily due to the decreased
levels of the hnRNP B1 isoform (Figure 2B). Both cell
lines expressed neuropeptide Y and neuronal marker genes,
i.e., growth associated protein 43 and microtubule-associated
protein 2, confirming their neuronal character (Supplementary
Figure S3).
We then used RA to differentiate the cells toward a neuronal
phenotype. We first tested the response of the two cell lines to
1µMRA (Figure 2C). As a rapid reduction in hASH1 levels upon
RA treatment of SH-SY5Y cells has been reported (Söderholm
et al., 1999), we monitored the decrease in hASH1 levels by
Western blot analysis in both cell lines in a time course of
up to 24 h. As expected, SH-SY5Y cells displayed a rapid
decrease in hASH1 levels that was noticeable as early as 3 h
(Figure 2C). Surprisingly, the Kelly cells maintained stable
hASH1 expression at early time points with a decline in
hASH1 levels becoming evident only at 18–24 h, which did not
reach the low levels observed in the SH-SY5Y cells (Figure 2C).
More interestingly, phase contrast microscopy revealed that these
changes in hASH1 levels correlated with the cells ability to
undergo the morphological changes associated with neuronal
differentiation (Figures 2D,E). Although the SH-SY5Y cells
contain small neurites even in the absence of retinoids, RA
treatment enhanced neurite outgrowth in these cells. However,
no similar morphological change was observed in the Kelly
cells. Both cell lines responded to RA by down-regulating
hASH1 mRNA and protein confirming that RA was indeed
active in these cells (Figures 3A,B). Consistently, both cell
lines also responded to RA by decreasing neuropeptide Y levels
(Figure 3C); a decrease in levels of neuropeptide Y in RA-treated
SH-SY5Y has already been documented (Edsjö et al., 2004).
Although a higher concentration of RA was more effective at
stimulating differentiation as assessed by the development of
neurite-like processes in the SH-SY5Y cells (Figure 3D), the
Kelly cells remained morphologically resistant to RA and lacked
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FIGURE 3 | Kelly cells are responsive to RA but resistant to RA-induced differentiation. (A) Decrease in hASH1 levels upon 1 and 10 µM RA treatment at
24 h monitored by real-time PCR and (B) Western blot analysis.∗∗∗p < 0.001 and ∗p < 0.05. Error bars indicate standard deviation (n = 6). (C) Real-time PCR
analysis of NPY levels upon RA treatment as in (A). Significant differences are indicated with asterisks ∗∗∗p < 0.001 and ∗∗p < 0.01. Error bars indicate standard
(Continued)
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FIGURE 3 | Continued
deviation (n = 3). (D) Phase contrast images showing concentration
dependent effect of RA on the morphology of Kelly and SH-SY5Y cells. Note
the formation of neurite-like processes in the RA-treated SH-SY5Y cells,
whereas Kelly cells did not respond morphologically to RA. Percentage of
neurite containing cells were counted as in Figure 2E. ∗∗p < 0.01, ∗p < 0.05,
nc: not counted as no cells matching the above criteria were observed, and
ns: not significant. Error bars indicate standard deviation (n = 3). (E) Kelly and
SH-SY5Y cells were treated with 10 µM RA for 4 days and hASH1 mRNA
levels monitored by real time PCR analysis. Values were normalized to 18S
ribosomal RNA and significant differences indicated with asterisks
(∗∗p < 0.01 and ∗∗∗p < 0.001). Error bars indicate standard deviation (n = 3).
(F) Kelly and SH-SY5Y cells were treated with 10 µM RA and imaged at
day 4. Percentage of differentiated cells were defined as those with neurite
extensions at least two times the length of the cell body. The total number of
cells were counted for each cell type and treatment and the percentage of
differentiated cells for the SH-SY5Y cells indicated. ∗∗∗p < 0.001. Error bars
indicate standard deviation (n = 3). Note that for the Kelly cells, the neurite
extensions did not fit our criteria to be counted as differentiated.
the neurite-like processes despite a similar down-regulation of
hASH1 mRNA and protein levels (Figures 3A–C). Longer RA
treatment times up to 4 days confirmed the resistance of majority
of the Kelly cells to RA-induced differentiation (Figures 3E,F).
The SH-SY5Y cells, on the other hand, showed an intense
neurite network after a 4 day exposure to RA and a concomitant
strong down-regulation in hASH1 (Figures 3E,F). Although the
variability inherent to different cell lines raises the possibility
of cell-type specific effects in the regulation of RA-induced
differentiation, these data suggest that high hASH1 expression
during the early phase of RA treatment inhibits the phenotypic
changes associated with retinoid induced differentiation.
hASH1 Suppresses RA-Induced
Differentiation
To determine if indeed hASH1 is responsible for the observed
lack of responsiveness of the Kelly cells to RA, we silenced
hASH1 in these cells by RNA interference. The efficiency of
silencing was determined by Western blot analysis at 2 days
post-transfection (Figure 4A). Interestingly, knock-down of
hASH1 had no effect on hnRNP A2/B1 that we have shown
previously to regulate hASH1 levels (Kasim et al., 2014). We
next investigated the response of these Kelly cells with high
(siControl) and with reduced hASH1 levels (sihASH1) to RA
treatment for 4 days. We found that both siControl and
sihASH1 cells responded effectively to RA by down-regulating
hASH1 (Figure 4B). The sihASH1 cells retained their lower
level of hASH1 for the course of the experiment (Figure 4B,
compare siControl to sihASH1) and their lower hASH1 level is
also reflected in their significantly lower levels of hASH1 at the
end of RA treatment (Figure 4B, compare siControl + RA to
sihASH1 + RA). Morphological examination by phase contrast
microscopy revealed that in comparison to siControl cells,
more RA-treated si-hASH1 Kelly cells developed neurite-like
processes (Figures 4C,D). There was no significant difference
in neurite length between differentiated cells obtained from the
high and low hASH1 expressing cells (Figure 4E). Qualitatively
similar results were obtained by silencing hnRNP A2/B1 that has
previously been documented to decrease hASH1 protein levels
(Supplementary Figure S4; Kasim et al., 2014), thus providing
additional evidence for the inhibitory effect of high hASH1 on
neuronal differentiation.
The data described above indicate that hASH1 prevents
RA-induced differentiation of neuroblastoma cells. To further
prove the specificity of hASH1 in regulating this effect, we
examined the hASH1-dependent RA-differentiation response
in SH-SY5Y cells that have a lower basal expression of
hASH1. We transiently overexpressed hASH1 in these cells
(Figure 4F). Interestingly, ectopically expressed hASH1 had a
lower molecular mass indicative of the non-phosphorylated form
of hASH1 and unlike endogenous hASH1 that is phosphorylated
in neuroblastoma cell lines (Wylie et al., 2015). Co-transfection
with EGFP allowed for visualization of hASH1 transfected
cells by fluorescence microscopy and allowed for live-cell
imaging to monitor cell morphology following RA treatment.
Since the hASH1 and EGFP plasmids were transfected at
a 9:1 ratio, fluorescent cells are expected to overexpress
hASH1. We confirmed the overexpression of hASH1 in the
co-transfected cells by immunofluorescence microscopy and by
co-localization of hASH1 and EGFP (Supplementary Figure
S5). The EGFP + hASH1 co-transfected cells expressed up
to 9.6-fold higher levels of hASH1 compared to the control
EGFP transfected cells (Supplementary Figure S5). These
transfected cells were then allowed to differentiate with RA
for 4 days. The EGFP alone expressing cells also served
as a transfection control and developed long neurites by
day 4 of differentiation (Figure 4G, left upper panel, white
arrowheads), while hASH1 overexpression strikingly diminished
neurite extension in the majority of the cells (Figure 4G, right
upper panels, red arrowheads). Notably, hASH1 overexpression
resulted in a significant decrease in the number of differentiated
cells (Figure 4H). There was no significant difference in neurite
length between the differentiated cells from the control or high
hASH1 overexpressing cell line (Figure 4I). Overlay of the
fluorescent images on the phase contrast images confirmed the
efficacy of RA to induce differentiation in both cell populations
as the non-transfected cells in each showed a similar degree
of neurite outgrowth (Figure 4G, lower panels). As EGFP
alone had no influence on neurite extension, we conclude that
overexpression of hASH1 inhibits neurite extension. Thus, our
findings in the two cell lines reveal a universal role for hASH1 in
regulating RA differentiation.
hASH1 Represses Retinoic Acid Receptor
Element-Dependent Transcription
To gain insight into the molecular mechanism behind
hASH1 repression of RA-induced differentiation, we examined
the effect of hASH1 on RA-dependent transcription at a
retinoic acid response element (RARE) in the context of a
luciferase reporter construct. We first reduced hASH1 levels
by siRNA-mediated knockdown in Kelly cells prior to RA
treatment. As shown in Figure 5A, a 1.8 fold increase in
RA-dependent luciferase activity upon hASH1 knockdown
was observed, indicating a hASH1-dependent repression
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FIGURE 4 | hASH1 levels affect RA-induced differentiation in Kelly and SH-SY5Y cells. (A) siRNA mediated knock-down of hASH1 was performed in Kelly
cells and cells were harvested following 2 days of siRNA transfection (10 nM final concentration). A representative Western blot experiment is shown demonstrating
knock-down efficiency at the protein level (left panel) and quantitation of the data from n = 9 (right panel). (B) Kelly cells from (A) were allowed to differentiate for
4 days and the decrease in hASH1 levels monitored by real time PCR. Values were normalized to 18S ribosomal RNA and significant differences indicated with
asterisks (∗∗∗p < 0.001, ∗∗p < −0.01 and ∗p < 0.05). n = 8. (C) Kelly cells were imaged at day 4 of differentiation and the neurite-like processes indicated by red
arrowheads. (D) Cells from RA treated siControl and sihASH1 were counted and neurites measured using NeuronJ software (∗p < 0.05; total number of cells
counted for siControl + RA = 680 and sihASH1 + RA = 776). Data is expressed as the ratio of differentiated cells to total cells counted. (E) Box plot analysis of
(Continued)
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FIGURE 4 | (Continued
neurite length of the differentiated cells from siControl and sihASH1. ns = not
significant. (F) Western blot analysis of total cell populations of SH-SY5Y cells
over-expressing EGFP or EGFP + hASH1. Tubulin served as a loading control.
(G) SH-SY5Y cells overexpressing EGFP or EGFP + hASH1 were enabled to
differentiate with RA and imaged at day 4. Long neurite-like processes are
indicated by white arrowheads in the EGFP overexpressing cells and the
shorter processes with red arrowheads in the EGFP + hASH1 overexpressing
cells. (H) RA treated transfected cells were counted and neurites measured
using NeuronJ software (total number of cells counted for EGFP +
RA = 437 and EGFP + hASH1 + RA = 446). Data are expressed as the ratio of
differentiated cells to total transfected cells counted. (I) Box plot analysis of
neurite length of the differentiated cells from control and hASH1 transfected
cells. ns = not significant.
of retinoid activity. We then compared the retinoid
activity upon hASH1 overexpression in SH-SY5Y cells and
found that luciferase activity was significantly lower upon
hASH1 overexpression, again indicating a hASH1-dependent
repression of retinoid activity (Figure 5B). Collectively, these
data show that hASH1 represses RA-dependent transcription at
the RA receptor element.
FIGURE 5 | hASH1 represses RA-dependent transcription at the
retinoic acid response element (RARE). (A) Kelly cells transfected with
either control siRNA or siRNA targeting hASH1 or (B) SH-SY5Y cells
transfected with control plasmid or a plasmid expressing hASH1 were also
transfected with a control luciferase (CONTROL-LUC) reporter construct or a
luciferase plasmid containing the RARE-LUC. Transcription of RARE-LUC is
thus dependent on RA. Luminescence values were normalized to renilla




To explore the possibility of promoting differentiation of
the otherwise differentiation resistant Kelly cell line under
physiological circumstances, we used hypoxia as a tool to
first manipulate hASH1 levels (Kasim et al., 2014). To this
end, Kelly cells were preconditioned to hypoxia for 24 h, a
time point at which a strong reduction in hASH1 levels was
observed (Figure 6A). The efficacy of hypoxia treatment was
confirmed by up-regulation of hypoxia marker genes (aldolase
C and prolyl-4-hydroxylase) as well as the down-regulation in
NPY that has been previously documented (Figure 6A) (Jögi
et al., 2002). Immediately after 24 h of hypoxic preconditioning,
when these cells have lowered levels of hASH1, cells were
induced to differentiate with RA under normoxic conditions.
Control cells grown at normoxia for 24 h were processed
similarly. Western blot analysis confirmed the down-regulation
in hASH1 protein levels indicative of effective RA treatment
after both normoxia and hypoxia growth conditions (Figure 6B).
It is worth mentioning that no significant difference was
observed in hASH1 levels between the control and hypoxia
preconditioned cells when placed in normoxia for 24 h
(Figure 6B). However, only the hypoxia preconditioned cells,
with lower hASH1 levels at the time of RA treatment,
displayed retinoid-induced neurite-like processes that stained
positive for neurofilament L, which is expressed during
neuronal differentiation (Figures 6C–E). Taken together, our
data show that manipulation of hASH1 expression by hypoxia
influences the sensitivity of neuroblastoma cells to RA-induced
differentiation.
DISCUSSION
Neuroblastoma is one of the few malignancies capable of
spontaneous differentiation and regression (Maris et al., 2007).
Increasing the ability to induce neuroblastoma differentiation
is thus key to disease therapeutics; however, this is often
impeded by the acquired refractiveness of neuroblastoma to the
differentiation agent. Our data here revealed hASH1 to play a
decisive role in inhibiting the differentiation of neuroblastoma in
response to RA, a finding that may have important implications
in differentiation therapy.
We discovered a common function of hASH1 in inducing
genes involved in cell cycle and DNA repair while repressing
genes involved in neuron differentiation in neuroblastoma.
This was evident across a large number of neuroblastoma
tumors from three different datasets that were obtained using
different microarray platforms, thus supporting the clinical
significance of our findings. Interestingly, this function of
hASH1 in neuroblastomamirrors that of MYCN (Valentijn et al.,
2012). The ability of MYCN to repress neuron differentiation
was inferred from the neuronal expression of its negatively
regulated genes, most of which were not identified to be
correlated with hASH1 (data not shown; Valentijn et al., 2012).
It is possible that MYCN cooperates with hASH1 to exert a
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FIGURE 6 | Hypoxic preconditioning promotes RA-induced differentiation. (A) Representative Western blot showing decreased levels of hASH1 following
24 h of hypoxia (top panel). Tubulin served as a loading control. Efficacy of hypoxia treatment was monitored by real-time PCR analysis of hypoxia marker genes
prolyl-4-hydroxylase and aldolase C. hASH1, hnRNP A2/B1 and neuropeptide Y levels are shown in addition (bottom panel). Values were normalized to 18S
ribosomal RNA. Significant differences are indicated with asterisks ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05; n = 6. (B) Representative Western blot showing
hASH1 levels of control cells and cells preconditioned to hypoxia following RA treatment. Schematic of the experimental design is shown in the left panel. Values
were normalized to tubulin. Significant differences are indicated with an asterisk ∗p < 0.05 and ns: not significant; n = 6. (C) Phase contrast images of cells as
described in (B). Neurite-like processes in the hypoxia preconditioned cells are indicated by red arrows. (D) The number of RA treated cells expressing neurites and
the total number of cells were counted using NeuronJ software (∗∗∗p < 0.001; total number of cells counted for normoxia + RA = 2224 and hypoxia preconditioned +
RA = 2139). (E) Immunofluorescence assays showing neurofilament L staining of normoxia and hypoxia preconditioned cells treated with RA for 24 h.
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concerted effect, which is reflected in the observed correlation
of hASH1 expression with MYCN amplification. Nevertheless,
the over-representation of MYCN non-amplified tumors in
the neuroblastoma datasets that we used and the regulation
of the MYCN non-amplified SH-SY5Y cell differentiation by
hASH1 indicates that hASH1 function in neuron differentiation
in neuroblastoma is likely to be independent of MYCN
amplification status. The importance of this being underlined by
the fact thatMYCN amplification, although themost well-known
prognostic marker, is observed in only 22% of primary tumors
(Brodeur and Bagatell, 2014).
Given the lack of responsiveness of neuroblastomas to RA, the
negative association of hASH1 with neuron differentiation was of
particular interest as it provided the first clue to the inhibitory
role of hASH1 on differentiation. The two neuroblastoma cell
lines we used to confirm this are ideal examples of neuroblastoma
that are either responsive or non-responsive to differentiation
by RA. Interestingly, it was the low hASH1 expressing SH-SY5Y
cells that were capable of undergoing the morphological changes
associated with differentiation. In these cells, hASH1 levels
decreased more or less concomitantly with RA treatment,
evident as early as after 3 h. In contrast, majority of the
high hASH1 expressing Kelly cells failed to express neurite-like
processes even upon prolonged RA treatment. Here, it is
important to emphasize that RA was indeed active in the Kelly
cells, as evidenced by the down-regulation of NPY and also
hASH1; yet, despite the decreased hASH1 levels, the Kelly cells
failed to differentiate in response to RA. We assume that an
initial threshold level for hASH1 expression exists beyond which
the inhibitory effects on differentiation are observed. Therefore,
it is the basal hASH1 level at the time of RA exposure (early
phase) that is crucial in determining the differentiation fate of
the cells. This is particularly true for Kelly cells that do not show a
rapid decrease in hASH1 protein levels upon retinoid treatment.
The hASH1 levels in both cell lines correlated with hnRNP
B1 that is known to have a stabilizing effect on hASH1 mRNA
and protein and could also play a role in their different basal
hASH1 expression and their response to RA (Kasim et al.,
2014).
Several lines of evidence strongly suggest hASH1 to
be involved in modulating the cellular differentiation
in response to RA. First, down-regulation of hASH1 by
directly targeting the hASH1 gene by RNA interference in
high-hASH1 expressing Kelly neuroblastoma cells promoted
RA-induced differentiation. Conversely, over-expression of
hASH1 in low-hASH1 expressing SH-SY5Y neuroblastoma
cells conferred resistance to RA-induced differentiation.
Second, down-regulation of hASH1 by targeting a modulator
of hASH1, namely hnRNP A2/B1, also promoted RA-induced
differentiation. Third, hypoxic preconditioning that significantly
decreases hASH1 levels prior to RA treatment also enhanced
differentiation. Finally, the ability of hASH1 to modulate
RA-induced differentiation correlated with its influence on
transcription at the RA receptor element. The mechanistic basis
behind hASH1-dependent transcription repression is not known.
To date, a myriad of transcription regulatory proteins have been
described to influence retinoid signaling (Gudas and Wagner,
2011; Cunningham and Duester, 2015). For instance, Zinc Finger
Protein 423 was identified by a large-scale RNA interference
screen to be critically required for RA-induced differentiation
of neuroblastoma cells (Huang et al., 2009). Here, we identified
hASH1 to inhibit RA-induced transcription at the RA receptor
element, thus, acting as a possible co-repressor of retinoid
signaling. In this regard, binding of several proneural proteins
includingNeurogenin1, Neurogenin2 and hASH1 to RA receptor
in the absence of ligand has already been described (Lee et al.,
2009). We cannot, however, exclude the involvement of other
factors that are targets of hASH1 in mediating this response.
The known function of hASH1, a proneural transcription
factor belonging to the achaete-scute gene family, is to promote
neurogenesis by regulating the expression of differentiation
genes; a function that is conserved in all organisms (Huang et al.,
2014). In Drosophila, achaete-scute expression confers neural
identity to the developing neuroblast, whereas in mammalian
systems, expression is restricted to cells that already have neural
identity (Lo et al., 1991; Skeath and Carroll, 1992). Regulation
of hASH1 expression is critical to the development program
(Imayoshi et al., 2013). Our data suggest that aberrant regulation
of hASH1, leading to high hASH1 expression, would inhibit
differentiation and maintain neuronal cells in a proliferative
state. It is important to keep in mind that retinoid activity
in vivo reciprocally maintains hASH1 at carefully regulated levels
that in turn determines neuronal identities (Jacob et al., 2013).
Thus, the dysregulation of hASH1 in neuroblastoma could in
turn be linked to defects in the RA synthesis and metabolism
FIGURE 7 | Proposed model of hASH1 function in neuroblastoma. High
hASH1 levels in neuroblastoma inhibit RA-mediated transcription at the RARE
resulting in low differentiation efficiency (A). Exposure to hypoxia causes an
hnRNP A2/B1-dependent decrease in hASH1 levels (Kasim et al., 2014) and
thus promotes RA-induced differentiation and neurite outgrowth, resulting in
higher differentiation efficiency (B). Thus, hypoxic preconditioning could serve
to enhance retinoid efficacy during differentiation therapy, especially for tumors
refractive to RA. We propose that hASH1 levels in neuroblastoma is indicative
of their differentiation potential and thus their response to differentiation
therapy.
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pathway as has been described in glioblastoma (Campos et al.,
2015).
A summary of our findings is depicted in Figure 7. RA
remains one of the most potent inducers of differentiation
for neuroblastomas and several derivatives are used as therapy
for high-risk neuroblastomas (Reynolds et al., 2003). A high
tumor differentiation grade is associated with a positive
outcome. Since efficacy of RA in vivo is limited by the
refractiveness of many neuroblastomas, combination therapy
with, for instance, histone deacetylase inhibitors has been
applied (Hahn et al., 2008; Brodeur and Bagatell, 2014).
We propose that refractiveness to RA is a function of the
hASH1 levels in these tumors. One of the surprising observations
that we describe is that hypoxic preconditioning remarkably
enhanced RA-differentiation efficacy. These data suggest that
the local oxygen environment can serve as a tool to manipulate
hASH1 levels in neuroblastomas that could effectively facilitate
differentiation therapy. Here, we would like to add a cautionary
note and stress the point that these data were obtained from
cell lines in vitro. The Kelly and SH-SY5Y are two different cell
lines, and additional cell type-specific effects of hASH1 on the
regulation of RA-induced differentiation cannot be ruled out.
Despite the negative correlation between hASH1 and neuron
differentiation observed in neuroblastoma patients, future in vivo
studies aimed at evaluating the potential prognostic usefulness
of hASH1 in predicting the responsiveness of these tumors to
RA-based therapies are needed. Although other factors have
been described tomodulate RA differentiation in neuroblastoma,
hASH1 represents a unique target and a possible biomarker for
all neuroblastoma, independent of MYCN amplification status
(Shah et al., 2014; Cimmino et al., 2015; Heynen et al., 2016).
Future studies will focus on defining the mechanism of action of
hASH1 during the early phase of RA-differentiation, which may
reveal novel cellular targets of importance to retinoid therapy.
Taken together, this study highlights hASH1 to be a modulator
of retinoid-induced differentiation that is of potential clinical
significance to neuroblastoma.
AUTHOR CONTRIBUTIONS
MK, HS and MF designed experiments; MK, VH and MF
performed experiments; MK, VH, HS, PBP and MF analyzed
and interpreted the data, contributed to discussion; MK and MF
wrote the manuscript.
FUNDING
This work was supported by the Deutsche
Forschungsgemeinschaft (Grant FA 845/2-2 to MF).
ACKNOWLEDGMENTS
We thankDr.Michael Schupp for his gifts of retinoic acid and the
retinoic acid receptor element containing luciferase construct.
We also thank Jeannette Schmidt, Ulrike Neumann and Ursula
Kastner for excellent technical assistance.
SUPPLEMENTARY MATERIAL




Axelson, H. (2004). The Notch signaling cascade in neuroblastoma: role of the
basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett. 204, 171–178.
doi: 10.1016/s0304-3835(03)00453-1
Benko, E., Winkelmann, A., Meier, J. C., Persson, P. B., Scholz, H., and Fähling, M.
(2011). Phorbol-ester mediated suppression of hASH1 synthesis: multiple ways
to keep the level down. Front. Mol. Neurosci. 4:1. doi: 10.3389/fnmol.2011.
00001
Brodeur, G. M., and Bagatell, R. (2014). Mechanisms of neuroblastoma regression.
Nat. Rev. Clin. Oncol. 11, 704–713. doi: 10.1038/nrclinonc.2014.168
Campos, B., Weisang, S., Osswald, F., Ali, R., Sedlmeier, G., Bageritz, J., et al.
(2015). Retinoid resistance and multifaceted impairment of retinoic acid
synthesis in glioblastoma. Glia 63, 1850–1859. doi: 10.1002/glia.22849
Castro, D. S., Martynoga, B., Parras, C., Ramesh, V., Pacary, E., Johnston, C.,
et al. (2011). A novel function of the proneural factor Ascl1 in progenitor
proliferation identified by genome-wide characterization of its targets. Genes
Dev. 25, 930–945. doi: 10.1101/gad.627811
Cimmino, F., Pezone, L., Avitabile, M., Acierno, G., Andolfo, I., Capasso, M., et al.
(2015). Inhibition of hypoxia inducible factors combined with all-trans retinoic
acid treatment enhances glial transdifferentiation of neuroblastoma cells. Sci.
Rep. 5:11158. doi: 10.1038/srep11158
Cohn, S. L., Pearson, A. D., London, W. B., Monclair, T., Ambros, P. F.,
Brodeur, G. M., et al. (2009). The International Neuroblastoma Risk Group
(INRG) classification system: an INRG task force report. J. Clin. Oncol. 27,
289–297. doi: 10.1200/JCO.2008.16.6785
Cunningham, T. J., and Duester, G. (2015). Mechanisms of retinoic acid signalling
and its roles in organ and limb development. Nat. Rev. Mol. Cell Biol. 16,
110–123. doi: 10.1038/nrm3932
Edsjö, A., Nilsson, H., Vandesompele, J., Karlsson, J., Pattyn, F., Culp, L. A.,
et al. (2004). Neuroblastoma cells with overexpressed MYCN retain their
capacity to undergo neuronal differentiation. Lab. Invest. 84, 406–417. doi: 10.
1038/labinvest.3700061
Fähling, M., Mrowka, R., Steege, A., Kirschner, K. M., Benko, E., Forstera, B., et al.
(2009). Translational regulation of the human achaete-scute homologue-1 by
fragile X mental retardation protein. J. Biol. Chem. 284, 4255–4266. doi: 10.
1074/jbc.M807354200
Fähling, M., Mrowka, R., Steege, A., Martinka, P., Persson, P. B., and Thiele, B. J.
(2006). Heterogeneous nuclear ribonucleoprotein-A2/B1 modulate collagen
prolyl 4-hydroxylase, alpha (I) mRNA stability. J. Biol. Chem. 281, 9279–9286.
doi: 10.1074/jbc.m510925200
Grynfeld, A., Påhlman, S., and Axelson, H. (2000). Induced neuroblastoma
cell differentiation, associated with transient HES-1 activity and
reduced HASH-1 expression, is inhibited by Notch1. Int. J. Cancer
88, 401–410. doi: 10.1002/1097-0215(20001101)88:3<401::AID-IJC12>3.
3.CO;2-M
Gudas, L. J., and Wagner, J. A. (2011). Retinoids regulate stem cell
differentiation. J. Cell Physiol. 226, 322–330. doi: 10.1002/jcp.
22417
Hahn, C. K., Ross, K. N., Warrington, I. M., Mazitschek, R., Kanegai, C. M.,
Wright, R. D., et al. (2008). Expression-based screening identifies the
combination of histone deacetylase inhibitors and retinoids for neuroblastoma
differentiation. Proc. Natl. Acad. Sci. U S A 105, 9751–9756. doi: 10.1073/pnas.
0710413105
Heynen, G. J., Nevedomskaya, E., Palit, S., Jagalur Basheer, N., Lieftink, C.,
Schlicker, A., et al. (2016). Mastermind-like 3 controls proliferation and
differentiation in neuroblastoma. Mol. Cancer Res. 14, 411–422. doi: 10.
1158/1541-7786.MCR-15-0291-t
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 December 2016 | Volume 9 | Article 156
Kasim et al. hASH1 Suppresses Neuroblastoma Cell Differentiation
Huang, C., Chan, J. A., and Schuurmans, C. (2014). Proneural bHLH genes in
development and disease. Curr. Top. Dev. Biol. 110, 75–127. doi: 10.1016/B978-
0-12-405943-6.00002-6
Huang, S., Laoukili, J., Epping, M. T., Koster, J., Hölzel, M.,Westerman, B. A., et al.
(2009). ZNF423 is critically required for retinoic acid-induced differentiation
and is a marker of neuroblastoma outcome. Cancer Cell 15, 328–340. doi: 10.
1016/j.ccr.2009.02.023
Imayoshi, I., Isomura, A., Harima, Y., Kawaguchi, K., Kori, H., Miyachi, H.,
et al. (2013). Oscillatory control of factors determining multipotency and fate
in mouse neural progenitors. Science 342, 1203–1208. doi: 10.1126/science.
1242366
Isogai, E., Ohira, M., Ozaki, T., Oba, S., Nakamura, Y., and Nakagawara, A.
(2011). Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma
cell growth through transactivation of Mash1. PLoS One 6:e19297. doi: 10.
1371/journal.pone.0019297
Jacob, J., Kong, J., Moore, S., Milton, C., Sasai, N., Gonzalez-Quevedo, R., et al.
(2013). Retinoid acid specifies neuronal identity through graded expression of
Ascl1. Curr. Biol. 23, 412–418. doi: 10.1016/j.cub.2013.01.046
Jögi, A., Øra, I., Nilsson, H., Lindeheim, A., Makino, Y., Poellinger, L., et al.
(2002). Hypoxia alters gene expression in human neuroblastoma cells toward
an immature and neural crest-like phenotype. Proc. Natl. Acad. Sci. U S A 99,
7021–7026. doi: 10.1073/pnas.102660199
Kasim, M., Benko, E., Winkelmann, A., Mrowka, R., Staudacher, J. J.,
Persson, P. B., et al. (2014). Shutdown of achaete-scute homolog-1
expression by heterogeneous nuclear ribonucleoprotein (hnRNP)-
A2/B1 in hypoxia. J. Biol. Chem. 289, 26973–26988. doi: 10.1074/jbc.M114.
579391
Kocak, H., Ackermann, S., Hero, B., Kahlert, Y., Oberthuer, A., Juraeva, D., et al.
(2013). Hox-C9 activates the intrinsic pathway of apoptosis and is associated
with spontaneous regression in neuroblastoma. Cell Death Dis. 4:e586. doi: 10.
1038/cddis.2013.84
Lee, S., Lee, B., Lee, J. W., and Lee, S. K. (2009). Retinoid signaling and
neurogenin2 function are coupled for the specification of spinal motor neurons
through a chromatinmodifier CBP.Neuron 62, 641–654. doi: 10.1016/j.neuron.
2009.04.025
Lo, L. C., Johnson, J. E., Wuenschell, C. W., Saito, T., and Anderson, D. J. (1991).
Mammalian achaete-scute homolog 1 is transiently expressed by spatially
restricted subsets of early neuroepithelial and neural crest cells. Genes Dev. 5,
1524–1537. doi: 10.1101/gad.5.9.1524
Maris, J. M., Hogarty, M. D., Bagatell, R., and Cohn, S. L. (2007).
Neuroblastoma. Lancet 369, 2106–2120. doi: 10.1016/S0140-6736(07)
60983-0
Raposo, A. A., Vasconcelos, F. F., Drechsel, D., Marie, C., Johnston, C.,
Dolle, D., et al. (2015). Ascl1 coordinately regulates gene expression and
the chromatin landscape during neurogenesis. Cell Rep. 10, 1544–1556.
doi: 10.1016/j.celrep.2015.02.025
Reynolds, C. P., Matthay, K. K., Villablanca, J. G., and Maurer, B. J. (2003).
Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 197, 185–192.
doi: 10.1016/s0304-3835(03)00108-3
Russell, M. R., Penikis, A., Oldridge, D. A., Alvarez-Dominguez, J. R.,
McDaniel, L., Diamond, M., et al. (2015). CASC15-S is a tumor suppressor
lncRNA at the 6p22 neuroblastoma susceptibility locus. Cancer Res. 75,
3155–3166. doi: 10.1158/0008-5472.CAN-14-3613
Shah, N., Wang, J., Selich-Anderson, J., Graham, G., Siddiqui, H., Li, X., et al.
(2014). PBX1 is a favorable prognostic biomarker as it modulates 13-cis
retinoic acid-mediated differentiation in neuroblastoma. Clin. Cancer Res. 20,
4400–4412. doi: 10.1158/1078-0432.ccr-13-1486
Skeath, J. B., and Carroll, S. B. (1992). Regulation of proneural gene expression and
cell fate during neuroblast segregation in the Drosophila embryo. Development
114, 939–946.
Söderholm, H., Ortoft, E., Johansson, I., Ljungberg, J., Larsson, C., Axelson, H.,
et al. (1999). Human achaete-scute homologue 1 (HASH-1) is downregulated
in differentiating neuroblastoma cells. Biochem. Biophys. Res. Commun. 256,
557–563. doi: 10.1006/bbrc.1999.0314
Valentijn, L. J., Koster, J., Haneveld, F., Aissa, R. A., van Sluis, P., Broekmans,M. E.,
et al. (2012). Functional MYCN signature predicts outcome of neuroblastoma
irrespective of MYCN amplification. Proc. Natl. Acad. Sci. U S A 109,
19190–19195. doi: 10.1073/pnas.1208215109
Wylie, L. A., Hardwick, L. J., Papkovskaia, T. D., Thiele, C. J., and Philpott, A.
(2015). Ascl1 phospho-status regulates neuronal differentiation in a Xenopus
developmental model of neuroblastoma. Dis. Model. Mech. 8, 429–441. doi: 10.
1242/dev.125153
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Kasim, Heβ, Scholz, Persson and Fähling. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution and reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 14 December 2016 | Volume 9 | Article 156
